Cookies on this site

In this Science Blog published on Oxford University website, Prof Paul Newton, Head of the Medicine Quality Group at the Infectious Diseases Data Observatory (IDDO) and the MORU Tropical Health Network and NDM Professor of Tropical Medicine i, explains the need for new strategies for tackling poor quality medical products.

Pills

Similar stories

Inside the Medicine Quality Monitoring Globe: tracking medicine quality risks in real time

A new study sets the development and the process powering the Medicine Quality Monitoring Globe, the interactive, online tool that maps real-time medicine quality reports in the media. As of October 2026, the system has captured 2.5 million articles.

Medicine Quality Research Group awarded £3.7 million to evaluate devices for detecting substandard and falsified vaccines

The Medical Research Council (UK) has awarded a £ 3.7 million DPFS grant to expand the work led by the Medicine Quality Research Group on innovative screening devices for detecting degraded and falsified vaccines.

Congratulations to our new Associate Professors 2026

Our heartfelt congratulations to Cindy Chu, Liz Batty and Tom Peto who have been awarded Associate Professorships

30 years of MORU research in Rickettsioses featured in ESCMID 2026 keynote

MORU was well represented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2026 conference, held from 17-21 April in Munich.

MODRA Cohort 2: From ideas to action

Following the success of the first MODRA workshop in September, where participants developed strong research grant proposals, the MODRA Cohort 2 researchers reconvened at OUCRU Ho Chi Minh City for Workshop 2, focused on taking their projects from paper to practice.

Ensitrelvir shows strong antiviral activity against COVID-19 in first head-to-head comparison with Paxlovid

The oral antiviral ensitrelvir is a highly effective treatment for COVID-19, showing potent in-vivo antiviral activity comparable to ritonavir-boosted nirmatrelvir (Paxlovid), say MORU, Mahidol and University of Oxford researchers in a major international study published in The Lancet Infectious Diseases.

Similar stories

Inside the Medicine Quality Monitoring Globe: tracking medicine quality risks in real time

A new study sets the development and the process powering the Medicine Quality Monitoring Globe, the interactive, online tool that maps real-time medicine quality reports in the media. As of October 2026, the system has captured 2.5 million articles.

Medicine Quality Research Group awarded £3.7 million to evaluate devices for detecting substandard and falsified vaccines

The Medical Research Council (UK) has awarded a £ 3.7 million DPFS grant to expand the work led by the Medicine Quality Research Group on innovative screening devices for detecting degraded and falsified vaccines.

Congratulations to our new Associate Professors 2026

Our heartfelt congratulations to Cindy Chu, Liz Batty and Tom Peto who have been awarded Associate Professorships

30 years of MORU research in Rickettsioses featured in ESCMID 2026 keynote

MORU was well represented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2026 conference, held from 17-21 April in Munich.

MODRA Cohort 2: From ideas to action

Following the success of the first MODRA workshop in September, where participants developed strong research grant proposals, the MODRA Cohort 2 researchers reconvened at OUCRU Ho Chi Minh City for Workshop 2, focused on taking their projects from paper to practice.

Ensitrelvir shows strong antiviral activity against COVID-19 in first head-to-head comparison with Paxlovid

The oral antiviral ensitrelvir is a highly effective treatment for COVID-19, showing potent in-vivo antiviral activity comparable to ritonavir-boosted nirmatrelvir (Paxlovid), say MORU, Mahidol and University of Oxford researchers in a major international study published in The Lancet Infectious Diseases.